Teva launches generic AndroGel

Press enter to search
Close search
Open Menu

Teva launches generic AndroGel

By Sandra Levy - 04/16/2019
Teva is introducing its generic AndroGel (testosterone gel 1.62%).

Testosterone gel 1.62%  is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism. It is a Schedule III controlled substance.

Testosterone gel 1.62% had a market value of more than $911 million, according to February 2019 IQVIA data.

RELATED TOPICS